Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy
Dejan Micić, Yuga Komaki, Aleksandar Alavanja, et al.
Journal of Clinical Gastroenterology (2017) Vol. 53, Iss. 1, pp. e1-e11
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Harnessing cytokines and chemokines for cancer therapy
David Propper, Frances R. Balkwill
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 4, pp. 237-253
Closed Access | Times Cited: 627
Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology
Benoı̂t L. Salomon, Mathieu Leclerc, Jimena Tosello, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 165
ECCO Guidelines on Inflammatory Bowel Disease and Malignancies
Hannah Gordon, Livia Biancone, Gionata Fiorino, et al.
Journal of Crohn s and Colitis (2022) Vol. 17, Iss. 6, pp. 827-854
Open Access | Times Cited: 155
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations
Alexander Nast, Catherine Smith, Phyllis I. Spuls, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 35, Iss. 2, pp. 281-317
Open Access | Times Cited: 149
Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems
Hicheme Hadji, Kawthar Bouchemal
Advanced Drug Delivery Reviews (2022) Vol. 181, pp. 114101-114101
Open Access | Times Cited: 70
Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group
Vasiliki Nikolaou, V. Sibaud, Davide Fattore, et al.
Journal of the American Academy of Dermatology (2020) Vol. 84, Iss. 5, pp. 1310-1320
Closed Access | Times Cited: 69
Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis
Pauline Raaschou, Jonas Söderling, Carl Turesson, et al.
Annals of Internal Medicine (2018) Vol. 169, Iss. 5, pp. 291-299
Closed Access | Times Cited: 64
Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study
Akbar K. Waljee, Peter Higgins, Camilla Bjørn Jensen, et al.
˜The œLancet. Gastroenterology & hepatology (2019) Vol. 5, Iss. 3, pp. 276-284
Closed Access | Times Cited: 54
German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations
Alexander Nast, Andreas Altenburg, Matthias Augustin, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2021) Vol. 19, Iss. 7, pp. 1092-1115
Open Access | Times Cited: 35
Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 2 «Manejo de poblaciones especiales, pacientes con comorbilidad y gestión del riesgo»
J.M. Carrascosa, L. Puig, I. Belinchón, et al.
Actas Dermo-Sifiliográficas (2022) Vol. 113, Iss. 6, pp. 583-609
Open Access | Times Cited: 24
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary
Jordan E. Axelrad, Jana G. Hashash, Steven H. Itzkowitz
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 7, pp. 1365-1372
Closed Access | Times Cited: 5
Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients with a HIstoRy of CancEr: SAPPHIRE Registry
Steven H. Itzkowitz, Yue Jiang, Cristina Villagra, et al.
Clinical Gastroenterology and Hepatology (2024)
Closed Access | Times Cited: 4
Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1389-1442
Open Access | Times Cited: 4
A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy
Wenhui Xie, Shiyu Xiao, Yanrong Huang, et al.
Lara D. Veeken (2019) Vol. 59, Iss. 5, pp. 930-939
Closed Access | Times Cited: 35
The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer
Panu Wetwittayakhlang, Paraskevi Tselekouni, Reem Al-Jabri, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 6, pp. 2432-2432
Open Access | Times Cited: 10
Psoriasis and cancer: the role of inflammation, immunosuppression, and cancer treatment
Manfredo Bruni, Fabio Lobefaro, Cristina Pellegrini, et al.
Expert Opinion on Biological Therapy (2025), pp. 1-17
Closed Access
Treatment sequencing in inflammatory bowel disease : towards clinical precision medicine
Léa Sequier, Bénédicte Caron, Sailish Honap, et al.
Best Practice & Research Clinical Gastroenterology (2025), pp. 101994-101994
Closed Access
Management of Patients with IBD and History of Cancer
Ilaria Faggiani, Sarah Bencardino, Mariangela Allocca, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1057-1057
Open Access
Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis
Kerasia‐Maria Plachouri, Sophia Georgiou
International Journal of Dermatology (2019) Vol. 58, Iss. 9, pp. 1008-1013
Closed Access | Times Cited: 26
The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
Eun‐Jung Park, Hyungjin Kim, Seung Min Jung, et al.
The Korean Journal of Internal Medicine (2020) Vol. 35, Iss. 1, pp. 41-59
Open Access | Times Cited: 26
Deutsche S3‐Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm – Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidität
Alexander Nast, Andreas Altenburg, Matthias Augustin, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2021) Vol. 19, Iss. 7, pp. 1092-1117
Open Access | Times Cited: 19
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
Kim Papp, Barbara Melosky, Sandeep Sehdev, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 4, pp. 867-889
Open Access | Times Cited: 8
The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus
Eun‐Jung Park, Hyungjin Kim, Seung Min Jung, et al.
Journal of Rheumatic Diseases (2020) Vol. 27, Iss. 1, pp. 4-4
Open Access | Times Cited: 20
Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta‐Analysis
Amélie Wetzman, Cédric Lukas, C. Gaujoux-Viala, et al.
Arthritis Care & Research (2021) Vol. 75, Iss. 2, pp. 260-271
Open Access | Times Cited: 18
Selecting first-line advanced therapy for ulcerative colitis: A clinical application of personalized medicine
Mariam S Mukhtar, Mahmoud Mosli
Saudi Journal of Gastroenterology (2024) Vol. 30, Iss. 3, pp. 126-137
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top